Compare SDGR & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SDGR | IOVA |
|---|---|---|
| Founded | 1990 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2020 | 2008 |
| Metric | SDGR | IOVA |
|---|---|---|
| Price | $30.46 | $14.23 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 10 |
| Target Price | ★ $21.43 | $10.70 |
| AVG Volume (30 Days) | 2.0M | ★ 12.3M |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.14 | 14.84 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $255,869,000.00 | N/A |
| Revenue This Year | N/A | $54.93 |
| Revenue Next Year | $3.12 | $40.91 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 23.29 | N/A |
| 52 Week Low | $10.95 | $1.76 |
| 52 Week High | $31.59 | $15.06 |
| Indicator | SDGR | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 73.76 | 86.63 |
| Support Level | $11.27 | $3.57 |
| Resistance Level | $31.59 | N/A |
| Average True Range (ATR) | 2.33 | 0.65 |
| MACD | 0.28 | 0.45 |
| Stochastic Oscillator | 90.69 | 95.63 |
Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.